Welcome to Decibel. You must be of legal age to enter this website, please confirm:
Formerly Westleaf Inc.

A biography of cannabis


Ian Brown Globe and Mail

In the end, all this fuss comes down to a plant.

The media frenzy about the legalization of cannabis in Canada on Oct. 17, the pumping and dumping of stocks, small craft cannabis growers versus $6-billion weed factories, the black market or the legal one, how the provinces will and won’t sell it, the vast claims (cures cancer!), the endless complaints (edibles won’t be legal for a year?) − is finally, in the end, about our strange and bottomless obsession with a saw-leaved weed.

Where did it come from? How does it grow? Why was it forbidden fruit for such a long time? What does it really do to us? And why are we so obsessed with it? Herewith, a short biography of the cannabis plant.

It’s an annual − a hardy weed that grows almost anywhere, from seed or (these days) from clippings and clones, indoors under lights or outdoors under nothing more than sunlight. The plants can be anywhere from less than a metre to six metres high. Male plants are frailer, and often culled before they pollinate the females. This makes the sexually frustrated females overproduce flowers, upon which grow the trichomes that produce the plant’s 113 cannabinoids − especially the two we care about most, psychoactive tetrahydrocannabinol (THC, the stuff that gets you high) and non-psychoactive cannabidiol (CBD, the nonintoxicating compound that calms people down). In general, the hotter and sunnier the growing climate, the more psychoactive the plant. Outdoors, some cannabis needs a three to five month growing season; indoors, fed hydroponically under artificial lighting and induced darkness (which in turn prompts the plants to bloom), a clever grower can produce three pounds of high-powered flower from 100 knee-high cloned plants (which might cover a large dining room table) every eight weeks.

But you don’t have to be a clever grower. The Mary.ag, a slick grow-box that sits in your living room and looks like a stereo speaker, controls watering and fertilization and odour electronically, via cellphone. The Mary produces 45 grams of smokeable flower every seven weeks. It costs US$499.

In general parlance (and exacting taxonomists have continuing objections to this), there are two widely accepted psychoactive variants of cannabis: harder-to-grow sativa, which is taller and skinnier and looks slightly hapless; and indica (shorter, bushier, tough guy). Neither plant wins beauty contests. The two subspecies are marketed in dispensaries, respectively, as energizing (sativa) and narcotic (indica). But − breaking news! a small scandal in the small world of cannabis research! − according to Vancouver’s Jonathan Page, a world expert on the cannabis genome and CEO of Anandia Laboratories Inc. (acquired two weeks ago by Aurora Cannabis Inc. for $115-million): “We’re having a lot of trouble showing that they’re genetically different. And also that there’s different chemistry between the two types, dopey-sleepy versus uplift.” For all the media attention cannabis gets, research on the plant is still in its infancy − as you might expect of a shrub that has been illegal in one form or another since the 1920s.

Cannabis evolved 65 million years ago. It was one of the earliest plants to be domesticated by humans, who have cultivated it for at least 10,000 years, starting with Neolithic man. (It was the Stone Age, dude). In 2008, a team of researchers in northwest China uncovered the grave of a Caucasian shaman buried 2,700 years ago with 700 grams of quad (high-grade AAAA cannabis indica) − “the good shuzzit,” as Louis Armstrong and his long-time dealer, Milton Mezzrow, called such stuff, and also the earliest physical evidence of human use of the psychoactive form of the drug. The earliest medical evidence of cannabis dates to the same era, also in China, where cannabis tea was recommended for a hundred ailments, including constipation, “female weakness” and absent-mindedness. One early Chinese doctor said cannabis in moderation lets users speak to spirits; in excess, he added, they become demons. Apparently, the advice to have “just one hit” has been ignored for centuries. The first cannabis plants grew wild − so say Robert Clarke and Mark Merlin, in their door-stopping Cannabis: Evolution and Ethnobotany − in the valleys of the Hindu Kush mountains between Afghanistan and Pakistan. From there, cannabis was traded and cultivated across Europe and Asia. Herodotus writes of Scythians (they were early horsemen, and established the Silk Road) “howling with pleasure in their hemp vapor baths.” As Martin Lee observes in Smoke Signals: A Social History of Marijuana (another excellent book upon which this article relies heavily), “Something about the herb resonated with humankind.”

“What is our society missing that we are so keen to bring cannabis back into it? What is it in the DNA of our society that puts cannabis on the front page of our newspapers every day?”

— Jonathan Page, world expert on the cannabis genome and CEO of Anandia Laboratories Inc.

 

The weed that went west and north, into Europe, tended to be hemp − that is, the leggy cannabis subspecies low in THC but excellent for rope, sails, clothing, paper, “hempcrete” and at least 3,000 other known uses that hemp fanatics will happily list. (Henry Ford built a hemp car that ran on hemp oil in the early 1940s). The plants that moved south into tropical India and Africa tended to be the psychotropic cultivars employed as medicine and for spiritual yayas. Daga has been used in Africa for at least 2,000 years: Zulus smoked it to relax and before battle, while pygmy tribes inhaled it through a mound in the earth and called it “earth smoking.” Today, Canadians vaporize cannabis oil through a water pipe and refer to it as dabbing. We’ve all been doing this a long, long time.

Most marijuana smoked in North America before the 1970s was grown in Mexico. When Mexico (under pressure from Ronald Reagan’s state department) sprayed its marijuana crops with the toxic plant killer paraquat, North Americans began to grow their own − indoors, to avoid detection. The war on drugs created a botanical revolution of historic proportions. Cannabis sativa, which produced a lighter, brighter, “talkier” high, was harder to grow in colder climates; the more narcotic and stonier indica subspecies could be grown everywhere, but it tended to induce couch lock. Growers (many of B.C.’s earliest were U.S. draft dodgers) soon combined the best of both worlds and produced seedless (hence sensimilla) hybrids of the two.

Indoor growing really took off in the 1980s with the invention of metal-halide and sodium grow lights. In 1982, U.S. law-enforcement agencies learned with alarm that the record tonnage of marijuana they seized was 38 per cent larger than the government’s estimate of the entire U.S. national crop that year. Cannabis plants that averaged 5 per cent to 8 per cent THC before the war on drugs were now capable of producing flowers with THC levels of 30 per cent and more.

Canada may be the first industrialized country to legalize cannabis for adult recreational use, but this isn’t the first time cannabis has been legal. From Pakistan, weed made its way around the world: to Europe and England both overland and from India, and to North and South America and everywhere in between via colonizing settlers and the slave trade from Africa. Richard Burton, the explorer and writer, used it for depression. Friedrich Nietzsche used it to wind down, Yeats and Wilde to wind up. Alexandre Dumas and Eugène Delacroix, the painter, smoked it with their famous pals at Paris’s Club des Hashischins.

The first crop of hemp cannabis in Canada was planted in Port Royal (now Nova Scotia) in 1606 by an apothecary accompanying Samuel de Champlain. France pressured the colonies to grow hemp for its navy, exempting the crop from the tithe paid to the Catholic Church, which in turn made the Catholic Church a sworn enemy of cannabis.

William Brooke O’Shaughnessy helped introduce cannabis to modern medicine after encountering the drug in Calcutta as an agent for the British East India Company. Upon his return to London in 1842 with a large stash of cannabis indica, he commissioned the manufacture of Squire’s Extract. Sir William’s chronic tonic actually relieved pain from rheumatism, quelled infant convulsions and calmed the spasms brought on by rabies and tetanus. Queen Victoria’s physician prescribed it for her menstrual cramps, and to others for what we would call Alzheimer’s.

The United States, so rabidly anti-drug for so long, was as keen on cannabis in the past as states such as California, Oregon and Washington are today. Mary Lincoln used it as a sedative after Abe’s assassination. The first two drafts of the Declaration of Independence were written on hemp paper. According to Dana Larsen’s Cannabis in Canada, F.W. Goodwin gave a lecture in 1897 that touted cannabis as a remedy for a raft of ailments, and also recommended it recreationally: It stimulated the appetite; induced sleep; gave users a sense of well-being “as if he had heard good tidings of great joy.” It also enhanced sexual pleasure, inducing a “powerful erection when the necessary mental stimulus is at hand,” which is an interesting way of putting it. However, it reduced the sensitivity of the member, which in turn lessened “premature discharge.” Dr. Goodwin was president of the Nova Scotia Medical Association.

“No one had a problem with cannabis then,” the legendary California cannabis activist Steve De Angelo told me recently. “Because it was being used by white people.”

How did such a popular plant become an object of hysterical hatred? The answer is no surprise given the current standoff at the U.S.-Mexico border: Cannabis became associated with immigrants and foreign labour during what Mr. Lee calls “an early twentieth century upsurge of nativism, scapegoating and political repression.”

Britain tried banning cannabis in the 1800s, over complaints about what it did to work habits on plantations: Slaves grew pot between rows of sugarcane and smoked it to lighten the drudgery of long hours of repetitive labour. By the early 20th century, after the prolonged Mexican revolution drove thousands of fleeing Mexicans into California, prohibitionists invented the threat of marijuana-crazed Mexicans and African-Americans to rail against immigration, tainting cannabis in the process. The anti-pot mania also infected Canada, where the spectre of black men puffing reefer and unemployed Chinese railway workers smoking opium were commingled and demonized by hugely popular writers such as Emily Murphy, who worked for Maclean’s Magazine under the byline Janey Canuck. She was also in favour of sterilizing “inferior” women.

Manias take hold of entire nations. Cannabis has inspired some notable developments in human culture − from Louis Armstrong’s improvisational jazz and Ella Fitzgerald’s scat singing and the Beatles’s Sgt. Pepper album to Jack Kerouac’s novels and Tommy Chong (a Canadian) and a good part of Woody Harrelson’s acting career. But Canada banned cannabis under the Opium and Narcotic Act as early as 1923. The prohibitionist frenzy didn’t abate until 70 years later, when the medical cannabis movement, in the form of compassion clubs, turned up in B.C., partly in response to the AIDS crisis.

By then, in the United States, Mr. Lee maintains, fifty separate government agencies were dedicated to inhibiting research into the therapeutic use of pot. Even in 2003, when Mr. Page took a job in Saskatoon at the National Research Council to study cannabis, he wasn’t allowed to buy or grow any: The NRC was an arm of the government, and it focused on the illegality of cannabis. Recent polls say a quarter of Canadians are still against legalization.

The problem is that prohibition has never worked. In 1937, 50,000 Americans smoked pot. By 1947, the number had doubled. In 2005, the year before California licensed its first six medical-marijuana clinics, more than 750,000 Americans were arrested on marijuana-related charges, most for simple possession, and most of them not white. In all, roughly two million people have been arrested for growing and selling pot in Canada; as recently as 2013, more than 59,000 people were arrested for possession. And yet somewhere between 183 million and 238 million people worldwide have tried or are users of cannabis. In the meantime, the governments of the United States and Canada have spent an estimated US$60-billion a year on the war on drugs. “Thirty years from now,” the writer and anthropologist Wade Davis has said, “the entire war on drugs will be seen as one of the greatest acts of folly in the history of public policy.” Meanwhile a third of Canadians plan to use cannabis when it goes legit on Oct. 17. People are already planning their parties. Big ones.

Cannabis is the only plant known to manufacture THC. It does this by siccing a series of enzymes upon a fatty-acid molecule and transforming it into an acid form of THC that, when it is heated or smoked, becomes psychoactive. (You can eat the leaves raw and not feel a thing.) All this action takes place in the trichomes on the surface of the resin-heavy flowers.

Things get even more interesting once THC is ingested into the human body by smoking or vaping or eating. It turns out − this is a fairly recent discovery − that the human body has its own (very ancient) set of endocannabinoid receptors in our central and peripheral nervous systems. These receptors bind to (among other agents) a neurotransmitter called anandamide, an endogenous cannabinoid − that is, one produced by our bodies. (Anandamide derives from the Sanskrit word “bliss.”) THC binds to the same receptors anandamide does, and does the same general thing anandamide does, except that it does it in a much blunter and more aggressive and more discombobulating way.

And what is that? That’s a question researchers are still answering in full. Like its in-house double, the retrograde anandamide, THC is a signal inhibitor − what Mr. Page refers to as “a kind of presynaptic dimmer switch that reduces the excitation of the neurons.” To put it (too) simply, cannabinoids such as THC (in conjunction with CBD and terpenes and many other cannabinoids, all of which work on one another to produce an “entourage effect”), slow down the messages barrelling back and forth through our synapses. This accounts for many of cannabis’s indicated medical effects − because cannabinoids reduce inflammation and pain, lower blood pressure, can stop seizures and relax muscles and quell epilepsy (and maybe migraines and fibromyalgia), seem to reduce spasticity and stiffness in people with multiple sclerosis, help with cramping, improve sleep, reduce nausea and calm PTSD. They may even be useful in weaning people off harder drugs. Opioids take pain away from patients, along with most alertness; cannabis, as one user once said to me, “takes you away from the pain.”

Or, to put it psychoactively, in addition to lowering the body’s pent-up physical pressures, cannabis spaces out the messages the mind and body send to each other incessantly, which in turn gives us time to notice what’s going on − that sense one has, using pot, that everything is happening for the first and most remarkable time. Michael Pollan, in his astonishing book The Botany of Desire, called it “the italicization of experience.”

Some researchers speculate that anandamide and other cannabinoids may be implicated in helping us forget − the short-term memory problem pot smokers experience − but in ways that are necessary and clarifying. Mr. Pollan thinks the main attraction of THC may be, in fact, the disarray and short-term memory loss it creates in the human brain. “The cannabinoid network appears to be part of that mechanism, vigilantly sifting the vast chaff of sense impressions from the level of perception we need to reach if we’re to get through the day and get done what needs to be done. All depends on forgetting.”

Cannabis does the same thing, just harder and faster. Cannabis makes it impossible to remember all the details that threaten to drown us, and lets us concentrate on them one after the other, laterally and forgetfully. It impairs us, but in doing so allows us to experience the world not as masters of the entire universe but as liberated goofball bystanders, freed from the world’s and our own blinding compulsions and expectations. Physiologically, cannabis disarms the bully Time, quiets its insistent tattoo of tick tick tick − leaving us to respond to the mere moment, possibly while laughing. And not just to respond to it, but to feel it, emotionally. It’s as if THC were a converter that transforms the matter we see and hold and hear and smell and taste into the wow of a more − for lack of a more comprehensive word − spiritual experience. At the very least, THC lets us be in the here and now, and experience the moment not as something to be rushed past but as something worth paying attention to.

The last time I spoke to Mr. Page, he ended our conversation by asking me a question. “What’s so special about cannabis?” he said. “What is our society missing that we are so keen to bring cannabis back into it? What is it in the DNA of our society that puts cannabis on the front page of our newspapers every day?” I thought about that for a while. Then he said “Someone characterized cannabis to me recently as the cure for the human condition.”

Maybe we can’t take our eyes off the cannabis plant because it serves a purpose. Maybe the evolutionary purpose of humanity’s ancient obsession with cannabis is that it can free us (momentarily) from the job of evolution − or at least from the relentless grind of it, of trying to survive with the fittest − which in turn allows us to simply be who we are, briefly, without regret, while high. Maybe it’s a spur to keep going. If cannabis is the cure for the human condition, which is that we are born to die, that we live only in order to sadly leave, cannabis may be all about forgetting. But it might also be a way to repeatedly forgive ourselves for our unwitting part in the calamity of being human.

Marijuana legalization Bill C-45 officially passes Senate vote, heading for royal assent


Monique Scotti Global News

The Senate has voted to accept the latest version of the government’s long-debated legal marijuana legislation, paving the way for the bill to pass into Canadian law.

The Senate voted 52-29 to approve the government’s newest version of Bill C-45 on Tuesday evening.

Bill C-45 now moves to royal assent, the final step in the legislative process. That could occur within days at the government’s discretion. The government’s desire to see home grown marijuana permitted across Canada eventually prevailed, and a proposal from the Senate to allow provinces and territories to ban them has been stripped from the final bill.

“We have witnessed today a very historic vote that ends 90 years of prohibition, that’s historic. It ends 90 years of needless criminalization, it ends a prohibition model that inhibited and discouraged public health, and community health approaches in favour of ‘just say no.’ Approaches that simply failed our young people miserably,” independent Senator Tony Dean said after the vote.

But not all Senators were happy with it.

“This bill does not do what the overarching goal says it does, which is to reduce the marijuana use among young people,” Tory Senator Leo Housakos said.

“The message for me is be very cautious, just because it’s legal doesn’t make it right. Educate yourself, and take cautious steps because what you do today will invariably have an impact on your life for years to come.”

Bill C-45 has been the subject of heated debate and uncertainty on Parliament Hill over the past several days. The conflict between the elected House of Commons and the unelected Senate ramped up last week with the government’s rejection of several key Senate amendments — most notably one linked to home cultivation.

 

Quebec, Manitoba and Nunavut have all decided they don’t want to allow home grows, in spite of the federal government’s desire to permit four plants per household. The Senate decided to side with the provinces, inserting a provision that would allow them to ban home grows if they desired.

Over the weekend and into Monday, however, there began to be indications that the Senate might defer to the government’s position.

In an interview on The West Block on Sunday, Dean, who sponsored the bill in the upper chamber, noted that while the Senate can provide advice, it’s the government that makes final decisions.

Then, on Monday, independent Sen. Andre Pratte, who had publicly supported the provincial bans, told reporters that while he felt the issue was important, “it’s not crucial” and not important enough to provoke a crisis.

“We know that it will come before the courts,” Pratte said. “That’s a case, even in the opinion of the Quebec government, that you’d have an excellent chance of winning.”

Court challenges may indeed be inevitable, and Quebec has already promised it will push back against any federal law that allows home-grows across the land.

A spokesperson for Manitoba’s justice minister told Global News on Tuesday that the minister is “satisfied that provinces have the legal authority to restrict home grown cannabis, up to and including prohibition” and that the Manitoba would be “willing to defend our position if challenged.”

Impaired driving bill still languishing

One other complication also remains: the government’s second marijuana bill, linked to drug-impaired driving. Bill C-46 includes new powers for police and harsher penalties for driving under the influence of alcohol or drugs, but like C-45, it contained some elements that the Senate wasn’t sure should be included.

Specifically, the upper chamber took exception to allowing police to force drivers to submit to random breath tests (without any reasonable suspicion of impairment) that could detect the active ingredient in marijuana.

The Senate removed that mandatory screening provision, which Justice Minister Jody-Wilson Raybould dubbed the “centrepiece” of the legislation, and sent C-46 back to the House of Commons. The government then rejected the Senate’s changes.

As of Tuesday, the issues surrounding Bill C-46 are still not resolved. The House of Commons is set to rise for the summer on Friday.

The enforcement of Canada’s new impaired driving laws, once they take effect, is also somewhat up in the air. Police currently rely on standard field sobriety tests, Drug Recognition Experts (DREs) and bodily fluid testing to detect impairment by drugs.

“Drug screening devices will assist with roadside testing,” said Mario Harel, president of the Canadian Association of Chiefs of Police, said an emailed statement.

“At this time, we await approval by the federal government as to which units will meet technical specifications and will be approved by the Minister of Justice and Attorney General of Canada. Until this process has been completed, police services are unable to make purchases and train officers in their use.”

Harel said that regardless of the status of drug screening devices, “we are very confident in our present processes, knowing that they will continually improve with time as we build capacity.”

From Palace Theatre to pot palace? Downtown landmark could play home to future cannabis store


Sammy Hudes Calgary Herald

Designated as a provincial and national historic site in 1996, changes to certain portions of the building would require approval from the province, if those parts have been designated for protection.

“It would all just depend on what they’re looking to develop at the site and if it is regulated by the province’s heritage designation,” said Josh Traptow, executive director of the Calgary Heritage Authority.

“I don’t think there would be a concern,” he said. “I think any time that heritage buildings have active use is a good thing. If you can create more opportunities for historical buildings, it’s a win-win for the owners of the site and the property.

The building has undergone a number of changes since it was built in 1921.

Billed as one of the grandest theatres in Western Canada during its early years, it served as the site of then-premier William Aberhart’s first radio broadcasts during the 1920s while forming the Social Credit party.

Until the opening of the Jubilee Auditorium in 1956, it was considered Calgary’s most prominent theatre and concert venue.

The Palace ran as a movie house until February 1990, when it showed its last film, Tango & Cash. It sat vacant until 1998 when it was converted into the Palace Night Club, which closed its doors in February 2004.

The venue was renamed Flames Central in 2007, as the Calgary Flames partnered with Concorde to turn the Palace into a hockey hub, calling it “a modern-day hybrid version of the interactive sports bar.” It went back to its original name in 2017 along with a broader scope.

Traptow said it’s not uncommon for heritage buildings to take on new uses, as a potential cannabis store would certainly do.

“I don’t think it would change the historical nature or anything like that,” he said.

“It’s always been a gathering place for Calgarians when it was a movie palace, and then when it went to kind of a more modern-day movie theatre and then the Flames Central, and now going back to Palace Theatre. It’s always been a place that Calgarians have gone to and I’m sure that it will continue to be as time progresses. Buildings go through natural changes and they find new purposes and new uses.”

Coun. Druh Farrell, whose ward includes the venue, expressed concern on social media Thursday about future pot shops abiding by all the necessary regulations that have been established.

“We have so many cannabis applications, I’m just stressing that we make sure they follow the rules,” she tweeted.

The province has estimated it will issue 250 cannabis retail licences during the first year of legalization, with no single retailer allowed to own more than 37 stores, or 15 per cent of the total licences.

As of late last month, about 250 would-be cannabis retailers had applied to do business in Calgary alone, none of which have been approved in the lead-up to legalization.

Changes to the land-use bylaws on cannabis stores will help determine how many stores end up opening in Calgary.

The city will have a 300-metre buffer zone between cannabis retailers, which will be prohibited from setting up within 150 metres of the property line of schools and emergency shelters.

Delta 9 Announces Letter of Intent with Westleaf Cannabis Inc. for Strategic Partnership and Expansion into Alberta


Delta 9 Cannabis

WINNIPEG, Jan. 29, 2018 /CNW/ – Delta 9 Cannabis Inc. (TSXV:NINE) (“Delta 9” or the “Company”) is pleased to announce it has entered into a non-binding letter of intent (the “LOI”) with Westleaf Cannabis Inc. (“Westleaf”) to create a strategic partnership for the joint development of a large-scale cannabis production facility located in Southern Alberta (the “Project”).

Pursuant to the terms of the LOI, Delta 9 and Westleaf will each own a 50 per cent equity interest in the Project. The Project includes the retrofit of an existing building intended to be equipped to produce approximately 4,000 kilograms of premium dried cannabis flower per annum, and an extraction lab for the production of cannabis oil and derivative products. Delta 9 anticipates designating the Project as an expansion facility under its existing Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license. The Project is expected to be operational as early as the third quarter of 2018 and is intended to supply cannabis products to the Alberta medical and recreational markets.

The completion of the Project remains subject to a number of conditions including, among other things: the execution of a definitive, binding agreement between Delta 9 and Westleaf; the parties obtaining the debt and equity financing required to complete the Project; and the completion of due diligence regarding the Project by Delta 9 and Westleaf.

“We are excited about this transformational opportunity,” said Delta 9 CEO John Arbuthnot. “Strategic partnerships with companies such as Westleaf provide Delta 9 with additional production capacity and expansion opportunities into new markets to meet increasing demand as we approach the legalization of recreational cannabis this summer.”

Westleaf President Scott Hurd says the Delta 9 partnership is an important step in his company’s development.

“We are extremely pleased to call Delta 9, one of Canada’s most experienced cannabis cultivators, our partner,” Hurd said. “Collectively, Westleaf and Delta 9 will have large-scale cannabis production facilities that can ably serve the Canadian Prairies (Alberta, Saskatchewan and Manitoba). “Our partnership will allow us to accelerate our time to market and drive synergies through collaboration to bring high quality, safe and consistent cannabis products to our medical and recreational customers.”

The completion of the Project by Delta 9 is also subject to final approval by the TSX Venture Exchange.

About Delta 9 Cannabis Inc.

Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an approximately 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”. www.delta9.ca

About Westleaf Cannabis Inc.

Westleaf is a private vertically integrated cannabis company headquartered in Calgary, Alberta. In addition to the Alberta Project, Westleaf is developing a ~200,000 square foot cannabis production facility in Saskatchewan. Westleaf and its affiliates are pursuing retail distribution in both Alberta and Saskatchewan. For more information please contact  info@localhost or visit our website at www.westleaf.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) the details and anticipated timing of the completion of the Project; (ii) the licensing of the Project; (iii) sales of cannabis produced by the Project; (iv) conditions required to complete the Project; and (v) the future development plans of Westleaf. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

 

SOURCE Delta 9 Cannabis Inc.

For further information: Gary Symons, Director of Communications, Delta 9 Cannabis Inc., 250.300.9352, communications@delta9.ca; Taylor Ethans, Westleaf Cannabis Inc., 403.618.5411, info@localhost